FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...

Tools

> Genta announced that it has struck definitive agreements with investors to place senior secured convertible notes due in 2010 totaling in aggregate up to $40 million in gross proceeds before fees and expenses. Release

> A Lehman Brothers analyst is bullish on Regeneron's cancer drug aflibercept, saying it compares well to Avastin. That opinion came after investors shaved 20 percent off the value of Regeneron shares after seeing disappointing data for ovarian cancer. Report

> The biotech start-up Iatrica is moving into new space at the John G. Rangos Building in East Baltimore. The building opened in April. Story

> Sangamo BioSciences has completed patient enrollment into its Phase II clinical trial in subjects with moderate to severe diabetic neuropathy. Release

> Topical applications of a naturally occurring fat molecule have the potential to slow down skin aging, whether through natural causes or damage, researchers report. Release

And Finally... Vaccine research is heading to outer space. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Cancer Drugs   Avastin   ovarian cancer   Sangamo BioSciences   Genta